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A B S T R A C T
The EuroFlow Consortium developed a fully standardized flow cytometric approach from instrument settings,
through antibody panel, reagents and sample preparation protocols, to data acquisition and analysis. The Swiss
Cytometry Society (SCS) promoted a study to evaluate the feasibility of using such standardized measurements
of 8-color data across two different flow cytometry platforms – Becton Dickinson (BD) FACSCanto II and
Beckman Coulter (BC) Navios, aiming at increasing reproducibility and inter-laboratory comparability of im-
munophenotypic data in clinical laboratories in Switzerland.
The study was performed in two phases, i.e. a learning phase (round 1) and an analytical phase (rounds 2 and
3) consisting of a total of three rounds. Overall, 10 laboratories using BD FACSCanto II (n= 6) or BC Navios
(n= 4) flow cytometers participated. Each laboratory measured peripheral blood samples from healthy donors
stained with a uniform antibody panel of reagents - EuroFlow Lymphoid Screening Tube (LST) – applying the
EuroFlow standardized protocols for instrument setup and sample preparation (www.EuroFlow.org). All data
files were analyzed centrally and median fluorescence intensity (MedFI) values for individual markers on defined
lymphocyte subsets were recorded; variability from reference MedFI values was assessed using performance
scores. Data troubleshooting and discussion of the results with the participants followed after each round at SCS
meetings.
The results of the learning phase demonstrated that standardized instrument setup and data acquisition are
feasible in routine clinical laboratories without previous experience with EuroFlow. During the analytical phase,
highly comparable data were obtained at the different laboratories using either BD FACSCanto II or BC Navios.
The coefficient of variation of MedFI for 7 of 11 markers performed repeatedly below 30%. In the last study
round, 89% of participants scored over 90% MedFI values within the acceptance criteria (P-score), in line with
the results of the EuroFlow quality assessment rounds performed by the EuroFlow expert laboratories(Kalina
et al., 2015). Central analysis of data allowed identification of deviations from the standardized procedures and
technical issues (e.g. failure to perform correct instrument setup and improper compensation).
In summary, here we show that inter-laboratory cross-platform standardization of 8-color flow cytometric
measurements in clinical laboratories is feasible and allows for fully comparable MedFI results across BD
FACSCanto II and BC Navios instruments. However, adherence to standardized protocols is crucial. Thus,
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training of the laboratory personnel in the EuroFlow standardized procedures is highly recommended to prevent
errors in instrument setup and sample preparation.
1. Introduction
Flow cytometry immunophenotyping has become a key tool for
diagnosis, classification, staging, and treatment response monitoring of
hematological and immunological disorders (Heel et al., 2017; Dongen
and Orfao, 2012).
As multicolor antibody panels used in clinical diagnostic labora-
tories provide increasing amounts of information about single cells
resulting in highly complex data sets, extensive expertise for correct
interpretation of flow cytometric data is required (Pedreira et al.,
2013). However, many clinical laboratories still continue to rely on
their own in-house antibody panels and instrument settings which in-
troduces considerable levels of subjectivity in flow cytometric analyses
whose results ultimately depend on the experience and knowledge of
local experts and the specific (highly variable) reagent panels applied in
different laboratories (Dongen and Orfao, 2012). In order to decrease
such subjectivity and variability in flow cytometric im-
munophenotyping measurements, consensus recommendations and
guidelines have been recently generated by several expert groups
(Johansson et al., 2014; Westers et al., 2012; Feller et al., 2013). De-
spite this, none of these groups attempted to standardize the whole flow
cytometric analysis process which is critical for obtaining reproducible
high quality data that are comparable at both the intra- and inter-la-
boratory levels over time. Such standardized measurements are indis-
pensable e.g. for high-sensitive minimal residual disease monitoring in
leukemia and lymphoma/myeloma (Flores-Montero et al., 2017;
Theunissen et al., 2016). Moreover, inter-laboratory comparable data is
essential for multicentric studies. Thereby standardization of flow cy-
tometric measurements is urgently needed. Since immunophenotyping
relies on the assessment of the level of expression of various markers on
one or more cell populations as assessed in a (semi)-quantitative
manner, achieving comparable median fluorescence intensity (MedFI)
measurements might be considered as an endpoint of standardization
across different laboratories.
In 2012, the EuroFlow Consortium developed a fully standardized
approach for immunophenotyping in hemato-oncology which covers
the whole flow cytometric analysis process from instrument setup
through antibody panels, reagents, and sample preparation protocols,
to innovative software tools and data analysis approaches (Kalina et al.,
2012; van Dongen et al., 2012) (www.euroflow.org). Subsequently, a
EuroFlow Quality Assessment (QA) program was developed in order to
control for the quality of data in individual laboratories that have im-
plemented the EuroFlow standard operating procedures (SOPs) (Kalina
et al., 2015).
Of note, full intra- and inter-laboratory reproducibility is also cri-
tical to implement the novel EuroFlow software-guided approaches for
automated classification of individual cells into specific cell popula-
tions, since this concept is based on direct comparison of flow cyto-
metry data files against well-defined databases of data files acquired in
different laboratories following standardized protocols (Pedreira et al.,
2013). Such automated analysis of locally acquired data files against
the EuroFlow databases might facilitate handling of increasingly com-
plex multicolor FCS data files and ease the classification of tumor cell
populations into specific disease entities (Costa et al., 2010). Conse-
quently, to take full advantage of the EuroFlow approaches, the mea-
surements of flow cytometric fluorescence and light scatter signals need
to be fully standardized.
Although the EuroFlow standardized approach was originally de-
veloped for BD FACSCanto II (BD Biosciences, San Jose, CA), it has been
successfully applied to other 8-color instruments available in
2006–2009, such as the BD LSRII (BD Biosciences) and Cyan ADP
(DakoCytomation) (Kalina et al., 2012). More recently, the EuroFlow
Consortium also proposed a standardized instrument setup procedure
for the Navios flow cytometer (Beckman Coulter, Miami, FL) (available
at www.euroflow.org), thus enabling generation of highly comparable
data across different flow cytometric platforms (Novakova et al., J
Immunol Methods, this issue).
The Swiss Cytometry Society (SCS) is dedicated to continuously
pursuing improvement in quality of flow cytometric measurements in
clinical laboratories across Switzerland. In 2014, the SCS started an
educational and training program aiming at standardization of flow
cytometric measurements to increase reproducibility and inter-labora-
tory comparability of immunophenotypic data in clinical laboratories in
Switzerland. Since the BD FACSCanto II and BC Navios instruments are
almost equally represented across clinical laboratories in Switzerland, a
cross-platform standardization was considered a prerequisite.
Here, we report on the results of the cross-platform standardization
feasibilty study performed in 10 different clinical laboratories across
Switzerland using either BD FACSCanto II or BC Navios instruments. In
addition, we also report on the specific technical issues encountered
and provide information on troubleshooting.
2. Materials and methods
2.1. Study outline
Standardized cytometer setup and sample preparation protocols
established by the EuroFlow Consortium were implemented by the 10
SCS clinical laboratories for this study (Kalina et al., 2012). Moreover,
the EuroFlow quality assessment (QA) scheme (Kalina et al., 2015) was
adopted in order to evaluate quality of the measured data. The only
laboratory with previous experience with EuroFlow standardization
(Aarau) coordinated the study. Whenever required by the participating
laboratories, the coordinating laboratory provided assistance or
training in the standardized EuroFlow procedures. The quality of data
for the EuroFlow Lymphoid Screening Tube (LST) measurements was
tested, using both fresh (< 24 h) peripheral blood from a healthy donor
distributed by the coordinating laboratory (round 1) and locally col-
lected fresh (< 24 h) peripheral blood samples from 3 healthy donors
(rounds 2 and 3) as a model. Evaluation of the data acquired was based
on the deviation of the measured median fluorescence intensity (MedFI)
of individual markers on predefined lymphocyte subsets from the ex-
pected MedFI established for the EuroFlow QA program and expressed
as “Performance score” (P-score) (Kalina et al., 2015). The corre-
sponding coeficients of variation (CV) for MedFI were calculated. In
total, three rounds were performed and results of each study round
were presented at the SCS meetings, where pitfalls were also discussed.
Subsequently, specific troubleshooting information was mailed to the
participating laboratories and published on the SCS website (www.
cytometry.ch).
2.2. Study rounds
The first round (learning phase) of the study took place in January
2014 and eight clinical laboratories using either BD FACSCanto II
(Aarau, Basel Hematology, Basel Immunology, Bellinzona, Bern,
Lucerne) or BC Navios instruments (Geneva, St. Gallen) participated.
Two independent QA rounds (analytical phase) followed in 2014 and
2015 in which nine clinical laboratories using BD FACSCanto II (n= 6)
or BC Navios (n= 3) participated. One laboratory participating in the
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first round with a BC Navios instrument (St. Gallen) was not able to
participate in the subsequent study rounds, and two new laboratories
using BC Navios (Lausanne, Zurich) joined the study for rounds 2 and 3.
One of the two new laboratories required assistance by the coordinating
laboratory to perform instrument setup.
2.3. Blood samples
For the first round, an EDTA peripheral blood sample from a healthy
donor was sent by the coordinating laboratory to each participating
laboratory. Staining of the sample in participating laboratories was
performed within 24 h after blood collection. For rounds 2 and 3, EDTA
peripheral blood samples from three healthy donors were obtained lo-
cally at each participating laboratory and processed within 24 h after
blood collection. The blood samples were obtained in accordance with
The Swiss Human Research Act and with approval of the local ethical
committee.
2.4. Reagents
The LST antibody cocktail – a lyophilized 8-color, 12-antibody
premixed reagent combination (CYT-LST) – kindly provided by
Cytognos SL (Salamanca, Spain) was used in all three study rounds. The
composition of the CYT-LST cocktail is as follows:
CD4 (clone RPA-T4) Pacific Blue, CD20 (clone 2H7) Pacific Blue,
CD45 (clone GA90) OC515, CD8 (clone UCHT-4) FITC, polyclonal anti-
IgLambda (IgL) FITC, CD56 (clone C5.9) PE, polyclonal anti-IgKappa
(IgK) PE, CD5 (clone UCHT-2) PerCP Cy5.5, CD19 (clone 19–1) PE-
Fig. 1. LST gating strategy.
Lymphocytes were selected upon eliminating doublets, debris, and non-leukocytic (CD45-negative) cells (upper row). Lymphocytes were gated as CD45-positive and SSClow events in
CD45 vs. SSC dot plot. Lymphocyte subpopulations were identified using relevant markers: CD19-positive B-cells represented in dark green were divided into IgL-positive (pink) and IgK-
positive (light green) subpopulations. CD3-positive T-cells (blue) were divided into CD8-positive (dark blue) and CD4-positive (orange). NK-cells (light blue) were identified as CD3/
CD19-double negative and CD56-positive events and the CD56-bright subpopulation of NK-cells was gated for analysis.
H. Glier, et al. Journal of Immunological Methods 475 (2019) 112348
3
Cyanine7 (PE Cy7), TCRγδ (clone TCR-1) PE Cy7, CD3 (clone 33-2A3)
APC, CD38 (clone LD38) APC C750. The EuroFlow-validated lot
(EAE01) of Rainbow Calibration Particles, 8 peaks (Spherotech, Lake
Forest, IL; referred thereafter in this manuscript to as Rainbow beads)
was used in all participating laboratories throughout the study. All the
required reagents were centrally acquired and distributed to the par-
ticipating laboratories by the coordinating laboratory.
2.5. Staining procedure
Specimen staining and erythrocyte lysis (BD FACS Lysing solution,
BD Biosciences) were performed using a stain/lyse/wash method as
described by the EuroFlow SOP for sample preparation and staining
(Part A: Common initial procedure when the EuroFlow antibody panel
includes SmIg staining and Part C: staining for surface markers only;
www.euroflow.org). All samples were acquired within 1 h after they
had been immunostained, using local flow cytometers.
2.6. Instruments
BD FACSCanto II flow cytometers were used in six laboratories and
BC Navios flow cytometers in four laboratories. All 3-laser instruments
were equipped with their standard optical configuration for a blue laser
emitting at 488 nm, a red laser emitting at 633 nm (BD FACSCanto II)
or 638 nm (BC Navios), and a violet laser emitting at 405 nm. Of note,
BC Navios instruments are equipped with two additional photo-
multiplier tubes (PMT) allowing detection of signals emitted by other
fluorochromes. Although the optical configuration of the two cyt-
ometers is generally similar, BC Navios differs substantially from BD
FACSCanto II flow cytometers in collection of the OC515 signal
(BP550/40 band pass filter vs. BP510/50 on BD FACSCanto II).
2.7. Instrument setup and compensation
Standardized instrument setup of the BD FACSCanto II and BC
Navios instruments was performed according to the EuroFlow SOP for
instrument setup and compensation (www.euroflow.org). Briefly, the
voltage of each PMT was set to reach the target mean fluorescence
intensity (MFI) for the 7th peak of the EuroFlow-validated Rainbow
beads lot (see www.euroflow.org). Fluorescence compensation was
calculated using Diva v6 (BD Biosciences) or Kaluza v1.2 or later
(Beckman Coulter) software, based on a defined set of single stained
peripheral blood compensation tubes as proposed by EuroFlow (see
www.euroflow.org).
2.8. Data analysis
Central analysis of all data files obtained on BD FACSCanto II (FCS
files) and BC Navios (LMD files) was performed by the coordinating
laboratory on “merged” data files (data files were combined into one
metafile for analysis and graphical presentation) using the Infinicyt
software v1.7 (Cytognos SL). Prior to merging FCS and LMD data files in
Infinicyt, the data were automatically rescaled by the software to a
common scale allowing simultaneous analysis of the digitalized signals
from distinct instruments. For data analysis, a predefined gating
strategy (Fig. 1) was used. Briefly, after excluding doublets and cell
debris, peripheral blood lymphocytes were gated in the side scatter
(SSClow) and CD45high area. Within lymphocytes, B-cells were gated as
CD19/CD20-double positive events and subsequently divided into IgK-
positive and IgL-positive subpopulations, T-cells were defined as CD3-
positive events and further gated into CD4-positive and CD8-positive T-
cells, and NK-cells were identified as CD3/CD19-double negative events
expressing CD56. Only CD56bright NK-cells were considered for analysis
in order to reduce heterogeneity in CD56 and CD38 expression by these
cells. For each of the above-defined lymphocyte subsets, MedFI values
for specific markers expressed by the gated lymphocyte subpopulations
were recorded and MedFI CVs were calculated (Table 1). Evaluation of
TCRγδ staining on T cells was not performed, as no P-score criteria were
defined for this subset in EuroFlow QA program (Kalina et al., 2015).
All gated lymphocyte subsets were displayed against the file numbers
for all fluorescence channels and data was visually inspected for any
potentially altered staining pattern. The presence of MedFI outlier va-
lues for individual samples was identified following P-score criteria and
the problems causing these inconsistencies were tracked down.
2.9. Statistical methods
The coefficients of variation (CV) of MedFI values recorded for each
marker analyzed on pre-defined lymphocyte subsets in individual FCS
and LMD files were calculated as:
CV = (standard deviation) / (average of MedFI) × 100 [%].
To quantify deviations from reference values the “Performance
score” (P-score) metrics was used as adopted by Kalina et al. (2015) for
EuroFlow QA program:
P-score = (log10MedFI-log10qaMedFI)/Dmax.
Briefly, P-score values were calculated as the difference of the
logarithmic transformation of an actual MedFI value from the loga-
rithmic transformation of all MedFI values from all QA rounds
(qaMedFI) and divided by Dmax. Dmax is the maximal allowed dif-
ference calculated as the 95th percentile of all absolute values of dif-
ference of actual MedFI from qaMedFI. To follow less stable values (IgL
FITC, and IgK PE; CV repeatedly> 60%), 90th percentile values were
used instead. Thus, P-score represents acceptance criteria for the MedFI
variation of each marker evaluated on its corresponding cell popula-
tion. A two-tailed Student's t-test (α = 0.05) was used to assess differ-
ences in MedFI values between BD FACSCanto II and BC Navios in-
struments.
3. Results
3.1. Round 1 (learning phase)
Median fluorescence intensity (MedFI) values for individual mar-
kers on well-defined lymphocyte subsets showed an average CV of
30.3% (range: 17.8%–47.5%) among all measurements. The CV of
MedFI for 7/11 markers was below 30% (Table 1). P-scores allowed for
rapid identification of MedFI outliers. Over 90% of all MedFI values in
6/8 laboratories (75% of measured samples/files) performed within the
P-score acceptance criteria (Table 2). Only one laboratory scored under
70% of MedFI values within P-score ranges not acceptable for QA, due
to failure to perform correct instrument setup (see 3.3 Pitfalls Section,
Table 1
MedFI variation during study.







CD20 PacB B-cells 27.8 14.2 14.1
CD4 PacB CD4pos T-cells 24.5 9.9 7.3
CD45 OC515 T-cells 38.5 23.4 17.1
CD8 FITC CD8pos T-cells 17.8 13.0 21.3
IgL FITC IgLpos B-cells 24.8 45.0 38.1
CD56 PE CD56bright NK-
cells
24.5 55.6 34.0
IgK PE IgKpos B-cells 47.5 80.0 59.2
CD5 PerCP
Cy5-5
T-cells 42.4 28.1 21.7
CD19 PE Cy7 B-cells 27.8 21.9 16.6
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and Fig. 2). No significant differences in MedFI between the data files
measured on BD FACSCanto II and BC Navios instruments were found
(see Table 3 for MedFI summary). Compensation errors were detected
in data files from 5 laboratories (see Fig. 2B and 3.3 Pitfalls Section for
details).
3.2. Rounds 2 and 3 (analytical phase)
The results of rounds 2 and 3 showed that highly comparable data
can be obtained across different laboratories using two different flow
cytometry platforms. However, inconsistent MedFI values in individual
laboratories were identified with P-score in both rounds. Symmetrical
shifts for MedFI values in triplicate samples from an individual la-
boratory would typically suggest systematic problems in that particular
laboratory, whereas individual outliers are rather related to the in-
dividual sample/donor. In each of the two rounds, 8/9 laboratories
(89%) scored above 90% values correct (within allowed P-score ranges)
and one laboratory scored 88% values correct (Table 2). No significant
differences in MedFI values for the analyzed lymphocyte subsets were
found among data files measured on BD FACSCanto II and BC Navios
instruments (see Table 3 for MedFI summary). Incorrect compensation
was observed in both, round 2 and round 3 (see 3.3 Pitfalls Section for
details).
In round 2, the MedFI values for markers on gated lymphocyte
subsets were distributed with an average CV of 32.9% (range:
9.9%–80.0%). Higher CVs were observed for IgK and IgL light chains
(80% and 45%, respectively) and for CD56 and CD38 on CD56bright NK-
cells (55.6% and 48.1%, respectively). The CV of MedFI for 7/11
markers systematically performed below 30%. In total, 12 individual
MedFI outliers were identified, one for each evaluated antigen and
corresponding lymphocyte subpopulation, with exception for CD4
(Pacific Blue channel) on T cells where 2 MedFI outliers in data files
from two different laboratories were identified. Further, decreased
MedFI values for IgK and IgL on B cells were observed in data files from
one laboratory (see 3.3 Pitfalls Section for more details).
In round 3, the MedFI values for individual markers on gated lym-
phocyte subsets were distributed with an average CV of 27.8% (range:
7.3%–59.2%). The highest CV was observed for IgK light chains
(59.2%) on B-cells followed by CD38 on CD56bright NK-cells (47.1%),
IgL light chains on B-cells (38.1%) and CD56 on CD56bright NK-cells
(34%). These results were comparable to those achieved by experienced
EuroFlow laboratories (Kalina et al., 2015). In total, 10 MedFI outliers
were identified, one for each evaluated antigen and corresponding
lymphocyte subpopulation, with exception for CD56 (PE channel) on
CD56bright NK-cells where no MedFI outlier was detected.
Importantly, an overall clear improvement in the quality of data was
achieved in rounds 2 and 3 vs. round 1, as documented by the overall
performance of the evaluated MedFI values for each laboratory
(Table 2).
3.3. Pitfalls
During central data analysis, Rainbow bead files acquired in in-
dividual laboratories during instrument setup were merged and ana-
lyzed prior to the LST data files. In the learning phase (round 1), lower
than expected MedFI values for the 7th peak of Rainbow beads were
observed in all fluorescence channels within one data file (Fig. 2A, la-
boratory 5). When closely evaluated, all 8 peaks of the Rainbow beads
appeared to be shifted towards lower fluorescence intensities in all
fluorescence channels, and the MedFI of the 8th peak of the Rainbow
beads seemed to be aligned with the 7th peak of the Rainbow beads in
the files measured in other laboratories (Fig. 2A: laboratory 5 vs. la-
boratories 1–4 and 6–8). Indeed, in that particular laboratory, the target
mean fluorescence intensity values for the 7th peak of the Rainbow
beads were applied to the 8th peak of the beads instead during in-
strument setup, resulting in incorrect photomultiplier (PMT) voltage
settings. These erroneous instrument settings where then used to ac-
quire the LST-stained peripheral blood sample which resulted in lower
MedFI values for all evaluated markers on gated lymphocyte sub-
populations (Fig. 2B; data file 5) as documented by rather poor per-
formance results of laboratory 5 in round 1 (Table 2).
Further, three laboratories (all BD FACSCanto II users) failed to
collect data on the height values for the light scatter signal (FSC-H) that
allow for gating of singlets and discrimination of doublets, respectively
(data not shown).
Most importantly, compensation errors were detected in all three
study rounds. Overcompensated data could be readily identified since
the MedFI values of those cell populations not expressing a given
marker typically shift towards negative values and pile on the axis
when a logarithmic scale is used to display MedFI of the data against
file number in Infinicyt software. In round 1, various markers in data
files from 5 different laboratories appeared to be overcompensated (see
Fig. 2B, black arrows). In one center, overcompensation for APC spil-
lover in the APC C750 channel resulted in a diminished CD38 signal on
NK-cells (data file 3 in Fig. 2B). During rounds 2 and 3, over-
compensated data could be spotted as symmetrical shifts in MedFI for
all three samples acquired in one laboratory. In round 2, data files ac-
quired in 6 participating laboratories exhibited improper compensation
for spillover in one or more of the following fluorescence channels:
FITC, PE, and PE Cy7 (data not shown). In round 3, data files acquired
in one participating laboratory showed improper compensation for
spillover in both FITC and PerCP Cy5.5 channels (see Fig. 3, data files
16–18), data files in two other laboratories exhibited erroneous com-
pensation for spillover in PE Cy7 channel (Fig. 3, data files 1–3 and
10–12).
Moreover, deviations from the EuroFlow SOP for sample prepara-
tion and staining could be identified, most strikingly insufficient
washing of the plasma from peripheral blood before staining with an-
tibodies against surface IgK and IgL light chains. This resulted in de-
creased labeling of IgK and IgL light chains on the surface of B cells and
subsequently, in lower MedFI signals measured due to antibody com-
petition with the abundant immunoglobulin molecules in the remaining
plasma, as illustrated in Fig. 4 where a data file with poor performance
score obtained in round 2 is displayed against a reference data file.
In addition, two BD FACSCanto II laboratories submitted data for
central analysis in a wrong format (“Diva Experiment” files instead of
FCS files). “Diva Experiment” files do not contain complete information
about the data as part of the information is saved separately within an
XML file which is exported together with “Diva Experiment” upon data
acquisition in Diva software. When third party software is used for data
analysis, the piece of information saved within the XML file cannot be
directly read by the software and the data might not be displayed
correctly. In this particular case we observed swapped FSC-W vs. FSC-H
and SSC-W vs. SSC-H parameters. Although the “Diva Experiment” files
bear an .fcs extension, they can be discriminated from FCS files by the
file name reading a consecutive number assigned to the files in Diva
Table 2
Summary results of all study rounds showing number of MedFI values within range for the
acceptable variation (P-score).
Correct MedFI values within P-score criteria per laboratory
Laboratory Round 1 Round 2 Round 3
1 11/11 (100.0%) 32/33 (97.0%) 33/33 (100.0%)
2 10/11 (90.9%) 31/33 (93.9%) 31/33 (93.9%)
3 9/11 (81.8%) 32/33 (97.0%) 31/33 (93.9%)
4 11/11 (100.0%) 33/33 (100.0%) 33/33 (100.0%)
5 7/11 (63.6%) 29/33 (87.9%) 31/33 (93.9%)
6 11/11 (100.0%) 30/33 (90.9%) 33/33 (100.0%)
7 11/11 (100.0%) 32/33 (97.0%) 33/33 (100.0%)
8 11/11 (100.0%) N/A N/A
9 N/A 32/33 (97.0%) 29/33 (87.9%)
10 N/A 33/33 (100.0%) 33/33 (100.0%)
H. Glier, et al. Journal of Immunological Methods 475 (2019) 112348
5
Fig. 2. Incorrect instrument setup during round 1.
Panel 2A shows results of cytometer setup using Rainbow beads. Dots represent MedFI of each of the 8 peaks of the Rainbow beads in their respective fluorescence channels. 7th peak
(reference) is highlighted in red. Laboratory 5 performed erroneous cytometer setup by applying the target values for the 7th peak of the Rainbow beads to the 8th peak instead
(highlighted in the red rectangle).
Panel 2B shows results of LST stained peripheral blood. Dots represent MedFI of each evaluated antigen/lymphocyte subpopulation pair. Each laboratory acquired one peripheral blood
sample. Erroneous instrument setup performed in laboratory 5 was used for acquisition of LST tube resulting in suboptimal MedFI values (highlighted in the red rectangle).
Overcompensated data can be identified piling on the vertical axes (indicated by black arrows). Color codes: IgL-positive B-cells (pink), IgK-positive B-cells (light green), CD8-positive T-
cells (dark blue), CD4-positive T-cells (orange), NK-cells (light blue). Laboratories 1–5 and 7 used BD FACSCanto II and laboratories 6 and 8 used BC Navios instruments.
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software. Data files from these laboratories were included in the central
analysis after re-submission in the correct FCS file format.
4. Discussion
In this study, we tested the feasibility of standardized flow
cytometric measurement of 8-color data in clinical laboratories, fol-
lowing the EuroFlow SOP, using two different flow cytometry plat-
forms: BD FACSCanto II and BC Navios.
For this purpose, we chose the LST antibody combination, as it re-
presents one of the most used ones in hematooncology and it is readily
available as EuroFlow-approved pre-mixed cocktail (www.cytognos.
Table 3
Summary of MedFI values obtained for analyzed lymphocyte subset and antigen pairs on Canto vs. Navios instruments.
Marker Cell subset Average of MedFI Canto vs. Navios
Round 1 (n= 8) Round 2 (n= 27) Round 3 (n= 27)
Canto (n= 6) Navios (n= 2) Canto (n= 6) Navios (n= 3) Canto (n= 6) Navios (n= 3)
CD20 PacB B-cells 19,827.10 20,450.23 20,538.95 18,296.60 21,331.20 20,611.69
CD4 PacB CD4pos T-cells 6345.70 6455.06 6275.69 5765.78 5981.54 5692.93
CD45 OC515 T-cells 5385.50 5651.04 5165.63 5033.88 5504.96 6424.42
CD8 FITC CD8pos T-cells 13,740.04 15,484.07 16,045.21 17,214.08 16,022.69 17,449.69
IgL FITC IgLpos B-cells 11,201.20 13,290.08 12,097.85 13,635.10 13,793.70 14,177.94
CD56 PE CD56bright NK-cells 13,362.45 15,379.33 3814.47 2721.99 3766.45 4464.17
IgK PE IgKpos B-cells 14,527.12 16,834.99 16,386.37 13,221.11 19,151.13 15,104.61
CD5 PerCP Cy5–5 T-cells 8403.47 8390.18 12,557.83 9449.73 9800.40 7661.82
CD19 PE Cy7 B-cells 15,079.81 16,930.35 14,657.23 15,163.43 18,174.25 16,382.86
CD3 APC T-cells 26,350.01 30,497.32 35,157.85 37,768.38 42,762.92 42,769.42
CD38 APC C750 CD56bright NK-cells 2723.66 3300.06 1649.62 2639.38 3647.42 3557.81
Fig. 3. Results of round 3.
Dots represent MedFI of each evaluated antigen/lymphocyte subpopulation pair. Each laboratory acquired three peripheral blood samples stained with LST tube. Highly comparable data
could be obtained using BD FACSCanto II (files 1–18) and BC Navios (files 19–27) cytometers. Black arrows indicate overcompensated data. Color codes: IgL-positive B-cells (pink), IgK-
positive B-cells (light green), CD8-positive T-cells (dark blue), CD4-positive T-cells (orange), NK-cells (light blue).
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com), as well as dried tube (van der Velden et al., 2017). In order to
eliminate the influence of lot-to-lot antibody variability on the MedFI
readouts (Böttcher et al., 2017), we used the same lot of a lyophilized
LST antibody mixture which was distributed to all participating la-
boratories by the coordinating laboratory. Moreover, during the
learning phase (round 1) we opted to use aliquots of one healthy donor
peripheral blood sample which was sent to participating laboratories,
too. This allowed us to directly assess technical issues and non-ad-
herence to SOP by the participants, as the impact of biological varia-
bility of the material as well as the variability of the reagents used could
be neglected. Discussion of the results of the learning phase (round 1)
with the participating laboratories allowed identification of critical
steps in the standardized EuroFlow protocols, and also the most
common errors in their execution.
In rounds 2 and 3 the MedFI values obtained for individual markers
on gated lymphocyte subsets were distributed with an average CV of
32.9% and 27.8%, respectively. The CV of MedFI for 7/11 markers
performed repeatedly under 30% in line with results of the EuroFlow
expert laboratories (Kalina et al., 2015). Higher CVs were observed for
IgK and IgL staining, as well as for CD38 and CD56 staining on
CD56bright NK-cells, which might also translate a greater biological
variability among B-cells and NK-cells from different donors for these
specific markers, respectively (Kalina et al., 2015). However, higher
CVs observed for IgK and IgL could also be, at least partially, caused by
non-adherence to standard sample preparation procedures, as discussed
hereafter.
Importantly, no significant differencies between BD FACSCanto II
and BC Navios were observed. In fact, almost identical MedFI values
were obtained on BD FACSCanto II and BC Navios instruments in dif-
ferent laboratories following the EuroFlow SOPs and the LST staining of
peripheral blood. In the GEIL study, Solly et al. (2013) reported su-
perimposable data between BD FACSCanto II and BC Navios
instruments when using 8-peak Rainbow beads and single-stained
CD16-positive granulocytes, however, they observed histogram shifts in
the PE Cy7 and APC Cy7 channels. Inter-laboratory studies published
by other groups did not attempt to fully standardize the measurements
and to evaluate the measured fluorescence signals (Feller et al., 2013;
Westers et al., 2012; Johansson et al., 2014). However, as the analysis
and interpretation of flow cytometric immunophenotyping data is
based on assessment of the level of expression of various markers on
different cell populations in a (semi)-quantitative manner, the flow
cytometric measurements need to be standardized and measured signal
expressed as MedFI may be used to evaluate the data quality, as proved
feasible here, for the first time in clinical laboratories in Switzerland.
The EuroFlow QA program (Kalina et al., 2015) was created to as-
sess quality of flow cytometric data using MedFI values as readout,
allowing for inter-laboratory comparison of standardized flow cyto-
metry measurements. We adopted the EuroFlow QA program and per-
formance score assessment, which allowed us to identify inconsistent
MedFI values in individual participating laboratories. All incon-
sistencies were tracked down and underlying technical problems and/
or non-adherence to the EuroFlow SOPs were identified. In study
rounds 2 and 3, 89% of participants scored 90% (P-score) values within
the acceptance criteria, in line with the results of the EuroFlow QA
rounds performed among EuroFlow expert laboratories (Kalina et al.,
2015). Interestingly, our results show that even laboratories without
previous experience with the EuroFlow approach can reach highly
comparable data by following the standardized EuroFlow protocols.
Despite this, several technical issues were identified during the
learning phase (round 1). The most striking was failure to perform
correct instrument setup when a wrong peak of the Rainbow beads was
taken as a reference for target mean fluorescence intensity setup. This
was, at least in part, due to the lack of previous experience with
Rainbow beads in that particular laboratory. This erroneous cytometer
Fig. 4. An example of a data file with a performance score of 64% compared to a reference data file.
Example of a data file with a poor MedFI performance score (results represented as dots) obtained in round 1 is displayed against the expected expression patterns (shown as reference
image contours). CD19, IgK and IgL on B-cells show lower fluorescence signal intensities than expected, as well as CD38 on NK-cells, whereas CD45 on T-cells shows higher signal
intensity than expected. Color codes: IgL-positive B-cells (pink), IgK-positive B-cells (light green), CD8-positive T-cells (dark blue), CD4-positive T-cells (orange), NK-cells (light blue).
H. Glier, et al. Journal of Immunological Methods 475 (2019) 112348
8
setup led to poor QA performance for MedFI values of this laboratory in
round 1 (< 70% acceptable P-score values), but not in subsequent
study rounds. No instrument setup problems were encountered in other
participating laboratories including those without previous experience
with the EuroFlow approach.
Non-adherence to standard sample preparation procedures could
also be identified in some laboratories, namely insufficient removal of
the plasma from peripheral blood before staining for surface IgK and
IgL light chains. This resulted in low labeling of IgK and IgL light chains
on the surface of B cells, due to interference of (abundant) plasma
immunoglobulins. However, the adherence to the SOPs was improved
upon discussion of the results with the participating laboratories, and
variability decreased e.g. in round 3.
Another issue noted in several participating laboratories was failure
to activate acquisition of the light scatter characteristics that would
allow doublet discrimination during data analysis. However, this failure
did not result in unacceptable QA performance.
Although the EuroFlow QA program adopted for the study was not
designed to assess fluorescence compensation, significant deviations
from the expected values could be readily detected. Thus incorrect
compensation was frequently found through both study phases and all
study rounds, consistent with those findings reported for the EuroFlow
QA rounds performed in EuroFlow expert laboratories (Kalina et al.,
2015).
A face-to-face participant meeting with discussion of the results and
troubleshooting was organized after each study round as a part of the
SCS meetings. All participating laboratories were provided with specific
troubleshooting notifications addressing the problems encountered,
their possible reasons and problem solutions. On-site (re)training was
performed by the coordinating laboratory when considered necessary
by the participating laboratories. Improvement of the QA results during
the study rounds 2 and 3 compared to round 1 documents the im-
portance of education, proper training and troubleshooting.
In summary, here we show that inter-laboratory cross-platform
standardization of 8-color flow cytometry measurements is feasible in
clinical laboratories without previous experience by using the EuroFlow
standardization protocols and SOPs. Highly comparable (almost iden-
tical) data between BD FACSCanto II and BC Navios instruments was
obtained following the EuroFlow standardized procedures for sample
preparation and instrument setup. However, proper training of la-
boratory personnel and adherence to the SOPs are essential for ob-
taining the desired standardization outcome.
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